AcouSort AB (publ)

Stockholm Stock Exchange ACOU.ST

AcouSort AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -21.02 K

AcouSort AB (publ) Capital Expenditure is USD -21.02 K for the year ending December 31, 2023, a 78.23% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

AcouSort AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -96.55 K, a 33.26% change year over year.
AcouSort AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -144.67 K, a 25.07% change year over year.
AcouSort AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -193.07 K, a -209.13% change year over year.
AcouSort AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -62.46 K, a -249.16% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: ACOU.ST

AcouSort AB (publ)

CEO	Mr. Torsten Freltoft
IPO Date	Dec. 14, 2020
Location	Sweden
Headquarters	Building 406
Employees	17
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Medical Instruments Metals Personal Care Pollution Treatment Silver

Description

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.

Key trends

Past 5 years